BullishAgent BullishAgent Filings Economic Earnings Ratings IPOs Insiders Institutional ETFs Funds Screener
Sign in Register

VCEL

Vericel Corporation NASDAQ Listed Feb 4, 1997
Healthcare ·Biotechnology ·US · vcel.com
$35.13
Mkt Cap $1.8B
52w Low $28.95 36.3% of range 52w High $45.97
50d MA $33.98 200d MA $35.69
P/E (TTM) 107.8x
EV/EBITDA 60.1x
P/B 5.1x
Debt/Equity 0.3x
ROE 4.7%
P/FCF 73.6x
RSI (14)
ATR (14)
Beta 1.21
50d MA $33.98
200d MA $35.69
Avg Volume 592.6K
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
SIC Code
2836
CIK (SEC)
Phone
617 588 5555
64 Sidney Street · Cambridge, MA 02139 · US
Data updated apr 27, 2026 7:24am · Source: massive.com